Table 5.
Multivariate Cox proportional hazards models for survival among non-mucinous invasive post-op study cases.
Model 1 | Model 2 | ||||
---|---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | ||
CA125 35–1750 (vs. <35) | 2.64 (1.15, 6.10) | 0.02 | 1.37 (0.57, 3.29) | 0.48 | |
CA125 >1750 (vs. <35) | 4.33 (1.81, 10.4) | 0.001 | 1.92 (0.76, 4.85) | 0.17 | |
p-trend for CA125 categories above* | <0.0001 | 0.04 | |||
Age (years) | 1.04 (0.88, 1.23) | 0.61 | 1.00 (0.84, 1.18) | 0.97 | |
Age (years), squared | 1.00 (1.00, 1.00) | 0.74 | 1.00 (1.00, 1.00) | 0.79 | |
Jewish | 1.02 (0.66, 1.58) | 0.94 | 0.92 (0.59, 1.44) | 0.73 | |
BMI (quintiles) | 1.01 (0.97, 1.04) | 0.80 | 1.01 (0.97, 1.04) | 0.72 | |
Parity (continuous) | 1.04 (0.94, 1.15) | 0.49 | 1.00 (0.90, 1.11) | 0.99 | |
Yeast infections | 1.39 (0.19, 10.4) | 0.75 | 1.17 (0.16, 8.68) | 0.88 | |
Appendectomy | 0.81 (0.54, 1.24) | 0.33 | 0.75 (0.49, 1.14) | 0.18 | |
Colitis | 2.09 (0.75, 5.78) | 0.16 | 2.53 (0.91, 7.04) | 0.07 | |
History of breast cancer | 1.03 (0.59, 1.79) | 0.93 | 1.06 (0.61, 1.86) | 0.83 | |
Endometrioid/clear cell (vs. serous) | 0.18 (0.09, 0.37) | <0.0001 | 0.35 (0.16, 0.76) | 0.008 | |
Mixed/other/Undiff. (vs. serous) | 0.52 (0.32, 0.83) | 0.006 | 0.54 (0.33, 0.86) | 0.01 | |
Stage 3–4 (vs. 1–2) | 2.57 (1.48, 4.47) | 0.0008 | |||
Ascites (any vs. none) | 1.99 (1.32, 3.01) | 0.001 |
The test for trend evaluates whether the association between categories of CA125 and survival increases or decreases across CA125 categories in a significantly linear pattern.